StreetInsider.com News Articles

Celldex reports sustained angioedema improvements 7 months post-treatment

Sun, 14 Jun 2026 14:00:55 -0400

Celldex Therapeutics (NASDAQ: CLDX) presented long-term results from its Phase 2 study of barzolvolimab at the European Academy of Allergy and Clinical Immunology Annual Meeting in Istanbul. The data showed that up to 64% of patients with chronic spontaneous urticaria (CSU) who had angioedema at baseline remained angioedema-free seven months after completing treatment.

The study involved 208 patients with CSU refractory to antihistamines who received various doses of barzolvolimab or placebo over a 52-week treatment period, followed by a 24-week follow-up period. Angioedema improvements began as early as Week 1 and were sustained at Week 76, seven months after the last

Celldex reports sustained angioedema improvements 7 months post-treatment

Sun, 14 Jun 2026 14:00:55 -0400

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual

Sun, 14 Jun 2026 10:21:00 -0400

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase

Celldex reports positive phase 1 results for bispecific antibody CDX-622

Sun, 14 Jun 2026 05:15:14 -0400

Celldex Therapeutics (NASDAQ: CLDX) presented results from a phase 1 study of CDX-622, a bispecific antibody targeting soluble stem cell factor and thymic stromal lymphopoietin, at the European Academy of Allergy and Clinical Immunology Annual Meeting in Istanbul.

The randomized, double-blind, placebo-controlled study enrolled 80 healthy participants across three parts examining single and multiple ascending doses. CDX-622 demonstrated rapid, dose-dependent reductions in serum tryptase levels, indicating mast cell depletion. The treatment was administered both intravenously and subcutaneously.

The drug was well-tolerated at all dose levels with no dose-limiting toxicities or serious adverse events reported. The most common side effect was grade 1

Celldex reports positive phase 1 results for bispecific antibody CDX-622

Sun, 14 Jun 2026 05:15:14 -0400

The drug was well-tolerated at all dose levels with no dose-limiting toxicities or serious adverse events reported. The most common side effect was grade 1

Celldex reports positive phase 1 results for bispecific antibody CDX-622

Sun, 14 Jun 2026 05:15:14 -0400

The drug was well-tolerated at all dose levels with no dose-limiting toxicities or serious adverse events reported. The most common side effect was grade 1

Celldex reports positive phase 1 results for bispecific antibody CDX-622

Sun, 14 Jun 2026 05:15:14 -0400

The drug was well-tolerated at all dose levels with no dose-limiting toxicities or serious adverse events reported. The most common side effect was grade 1

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Sun, 14 Jun 2026 05:15:00 -0400

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases
CDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functions
Rapid, profound, dose-dependent, and durable reductions in serum tryptase observed
Well-tolerated at all dose levels
First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cells